FI111542B - Menetelmä terapeuttisesti käyttökelpoisten imidatsolin rikkijohdannaisten valmistamiseksi - Google Patents

Menetelmä terapeuttisesti käyttökelpoisten imidatsolin rikkijohdannaisten valmistamiseksi Download PDF

Info

Publication number
FI111542B
FI111542B FI913250A FI913250A FI111542B FI 111542 B FI111542 B FI 111542B FI 913250 A FI913250 A FI 913250A FI 913250 A FI913250 A FI 913250A FI 111542 B FI111542 B FI 111542B
Authority
FI
Finland
Prior art keywords
radical
methyl
compound
butyl
imidazole
Prior art date
Application number
FI913250A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI913250A0 (fi
FI913250A (fi
Inventor
Gilles Hamon
Jean-Paul Vevert
Michel Fortin
Jean-Claude Caille
Alain Corbier
Simone Jouquey
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9008538A external-priority patent/FR2664271B1/fr
Priority claimed from FR9104882A external-priority patent/FR2675503B1/fr
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of FI913250A0 publication Critical patent/FI913250A0/fi
Publication of FI913250A publication Critical patent/FI913250A/fi
Application granted granted Critical
Publication of FI111542B publication Critical patent/FI111542B/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Epoxy Resins (AREA)
FI913250A 1990-07-05 1991-07-04 Menetelmä terapeuttisesti käyttökelpoisten imidatsolin rikkijohdannaisten valmistamiseksi FI111542B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR9008538A FR2664271B1 (fr) 1990-07-05 1990-07-05 Nouveaux derives soufres de l'imidazole, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant.
FR9008538 1990-07-05
FR9104882 1991-04-19
FR9104882A FR2675503B1 (fr) 1991-04-19 1991-04-19 Nouveaux derives soufres de l'imidazole, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant.

Publications (3)

Publication Number Publication Date
FI913250A0 FI913250A0 (fi) 1991-07-04
FI913250A FI913250A (fi) 1992-01-06
FI111542B true FI111542B (fi) 2003-08-15

Family

ID=26228128

Family Applications (1)

Application Number Title Priority Date Filing Date
FI913250A FI111542B (fi) 1990-07-05 1991-07-04 Menetelmä terapeuttisesti käyttökelpoisten imidatsolin rikkijohdannaisten valmistamiseksi

Country Status (21)

Country Link
US (3) US5412101A (ja)
EP (1) EP0465368B1 (ja)
JP (2) JP3192171B2 (ja)
KR (1) KR100216006B1 (ja)
CN (1) CN1045769C (ja)
AT (1) ATE166344T1 (ja)
AU (1) AU653160B2 (ja)
CA (1) CA2046265C (ja)
DE (1) DE69129428T2 (ja)
DK (1) DK0465368T3 (ja)
ES (1) ES2117001T3 (ja)
FI (1) FI111542B (ja)
HU (1) HU217444B (ja)
IE (1) IE912335A1 (ja)
IL (1) IL98319A (ja)
MA (1) MA22203A1 (ja)
MX (1) MX9100092A (ja)
OA (1) OA09506A (ja)
RU (1) RU2086542C1 (ja)
UA (1) UA26130A (ja)
WO (1) WO2004074258A1 (ja)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5616599A (en) * 1991-02-21 1997-04-01 Sankyo Company, Limited Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
FR2687674B1 (fr) * 1992-02-07 1995-05-19 Roussel Uclaf Nouveaux derives de la pyridone, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant.
DE69329982T2 (de) * 1992-06-02 2001-09-27 Sankyo Co., Ltd. 4-Carboxyimidazolderivate als Angiotensin-II-Antagonisten und ihre therapeutische Verwendung
GB9213934D0 (en) * 1992-06-30 1992-08-12 Smithkline Beecham Corp Chemical compounds
GB9218449D0 (en) 1992-08-29 1992-10-14 Boots Co Plc Therapeutic agents
IT1255461B (it) * 1992-07-28 1995-11-02 Luso Farmaco Inst Eteri di imidazoli ad attivita' a ii antagonista
US5376666A (en) * 1992-11-30 1994-12-27 The Du Pont Merck Pharmaceutical Company Angiotension-II receptor blocking, azacycloalkyl or azacycloalkenyl
JP3501484B2 (ja) * 1992-12-17 2004-03-02 三共株式会社 ビフェニル誘導体
FR2711367B1 (fr) * 1993-10-19 1995-12-01 Roussel Uclaf Nouveau procédé de préparation de dérivés soufrés de l'imidazole et les nouveaux intermédiaires obtenus.
US5395844A (en) * 1993-06-10 1995-03-07 The Du Pont Merck Pharmaceutical Company Imidazole 5-position substituted angiotensin II antagonists
US5409926A (en) * 1993-07-19 1995-04-25 Merck & Co., Inc. AT-2 antagonist inhibition of vascular restenosis
FR2716882B1 (fr) * 1994-03-04 1996-04-05 Roussel Uclaf Utilisation de dérivés de l'imidazole au traitement d'affections impliquant les récepteurs AT1 et AT2 de l'Angiotensine, certains de ces produits, leur préparation, compositions pharmaceutiques.
EP0786455B1 (en) * 1994-09-26 2003-12-03 Shionogi & Co., Ltd. Imidazole derivative
EP0855392A3 (de) 1997-01-22 2000-01-05 Hoechst Aktiengesellschaft Fünfgliedrige Heterocyclen mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19739113A1 (de) * 1997-09-06 1999-03-11 Gefinex Polymerschaeume Gmbh Vorexpandierte polyolefinische Schaumpartikel
DE19820064A1 (de) * 1998-05-06 1999-11-11 Hoechst Marion Roussel De Gmbh Substituierte Sulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
KR20010048940A (ko) * 1999-11-30 2001-06-15 서평원 프로세서의 디바이스 제어 시스템
JP4529119B2 (ja) * 2001-08-09 2010-08-25 小野薬品工業株式会社 カルボン酸誘導体化合物およびその化合物を有効成分として含有する薬剤
EP1752450A1 (en) 2005-08-01 2007-02-14 Merck Sante Imidazole derivatives as fructose-1,6-bisphosphatase inhibitors and pharmaceutical compositions containing them
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA3089569C (en) 2007-06-04 2023-12-05 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US20100120694A1 (en) 2008-06-04 2010-05-13 Synergy Pharmaceuticals, Inc. Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
US7828840B2 (en) 2007-11-15 2010-11-09 Med Institute, Inc. Medical devices and methods for local delivery of angiotensin II type 2 receptor antagonists
EP2321341B1 (en) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
JP5395905B2 (ja) * 2008-09-02 2014-01-22 エルダー・ファーマシューティカルズ・リミテッド 抗炎症化合物
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
JP2016514670A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
RS65632B1 (sr) 2013-06-05 2024-07-31 Bausch Health Ireland Ltd Ultra-prečišćeni agonisti guanilat-ciklaze c, postupak njihove pripreme i upotrebe
JP6807684B2 (ja) * 2016-09-08 2021-01-06 ナブテスコ株式会社 シールアダプタ

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179512A (en) * 1977-03-01 1979-12-18 Merck & Co., Inc. 4-Substituted-2-arylimidazoles
PT78388B (en) * 1983-04-12 1986-09-15 Smithkline Beckman Corp Dopamine-beta-hydroxylase inhibitors
CA1334092C (en) * 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US4882348A (en) * 1987-12-29 1989-11-21 Smithkline Beckman Corporation 2-(aminoalkylthio)imidazoles as dopamine-β-hydroxylase inhibitors
CA1338238C (en) * 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids

Also Published As

Publication number Publication date
JP3192171B2 (ja) 2001-07-23
AU653160B2 (en) 1994-09-22
DE69129428T2 (de) 1998-11-05
ATE166344T1 (de) 1998-06-15
RU2086542C1 (ru) 1997-08-10
IE912335A1 (en) 1992-01-15
CA2046265C (fr) 2005-10-18
JP3261403B2 (ja) 2002-03-04
US5412101A (en) 1995-05-02
MA22203A1 (fr) 1992-04-01
EP0465368B1 (fr) 1998-05-20
DK0465368T3 (da) 1999-03-08
FI913250A0 (fi) 1991-07-04
KR920002552A (ko) 1992-02-28
US5684028A (en) 1997-11-04
HU217444B (hu) 2000-01-28
HU912265D0 (en) 1991-12-30
EP0465368A1 (fr) 1992-01-08
UA26130A (uk) 1999-06-07
CA2046265A1 (fr) 1992-01-06
CN1058775A (zh) 1992-02-19
WO2004074258A1 (fr) 2004-09-02
FI913250A (fi) 1992-01-06
HUT58297A (en) 1992-02-28
CN1045769C (zh) 1999-10-20
US5599830A (en) 1997-02-04
IL98319A0 (en) 1992-06-21
IL98319A (en) 1997-04-15
JP2001151759A (ja) 2001-06-05
ES2117001T3 (es) 1998-08-01
JPH04230369A (ja) 1992-08-19
DE69129428D1 (de) 1998-06-25
MX9100092A (es) 1992-02-28
KR100216006B1 (ko) 1999-08-16
AU8016391A (en) 1992-01-09
OA09506A (fr) 1992-11-15

Similar Documents

Publication Publication Date Title
FI111542B (fi) Menetelmä terapeuttisesti käyttökelpoisten imidatsolin rikkijohdannaisten valmistamiseksi
KR101629356B1 (ko) 퀴나졸리논 유도체의 제조방법
US4788199A (en) Pharmacologically active amides, processes for their preparation and pharmaceutical compositions containing them
EP2089367B1 (en) Pyrazoline compounds as mineralocorticoid receptor antagonists
RU2049779C1 (ru) Производные 4-аминофенола или их n-алкильные или солевые производные, проявляющие противовоспалительную активность
RU2141321C1 (ru) Применение производных имидазола для приготовления фармкомпозиций, активных к рецепторам ат1 и ат2 ангиотензина, некоторые из этих соединений, способ получения производных имидазола и фармацевтические композиции на их основе
WO1991009024A1 (fr) Derive de l'acide quinazoline-3-alcanoique, sels derives de ce compose et sa production
RU2174513C2 (ru) Четырехзамещенные производные имидазола, способы их получения, промежуточные соединения и фармацевтическая композиция
KR100466991B1 (ko) 페닐이미다졸리딘유도체의신규제조방법
DE69431824T2 (de) Verfahren zur Herstellung von Schwefelhaltigen Imidazolderivaten und erhaltene Zwischenprodukte
US5527919A (en) Process for the preparation of 1-[(1,1'-biphenyl]-4-YL]-methyl-1H-imidazole-5-carboxylic acids
US4791114A (en) 2-Benzimidazolylalkylthio (or -sulfinyl or -sulfonyl) derivatives, their preparation and their application as medicinal products
FI101300B (fi) Menetelmä farmakologisesti aktiivisten 1,2,3,4-tetrahydrokinoliini-6-e tikkahappojohdannaisten valmistamiseksi ja välituotteena käytettävät k inoliinijohdannaiset
ES2241326T3 (es) Sulfonilcianamidas sustituidas, procedimiento para su preparacion y su uso como medicamento.
RU2171257C2 (ru) Производные имидазола, способы их получения, промежуточные вещества и фармацевтические композиции на основе производных имидазола
EP0287971A2 (en) Benzimidazole derivatives and process for their preparations
WO2010113952A1 (ja) ムスカリン受容体拮抗薬
HU195791B (en) Process for producing new, trisubstituted 1,2,4-triazol derivatives

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: HOECHST MARION ROUSSEL

MA Patent expired